Islet Sciences Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Islet Sciences Inc Announces New Chairman and Chief Executive Officer
Islet Sciences Inc announced changes to the Company`s senior management team and the board of directors. Michael M. Earley, most recently Chairman and Chief Executive Officer(CEO) of Metropolitan Health Networks, Inc. has been named Chairman of the board and CEO of the Company, succeeding John Steel, who remains a member of Islet Sciences` Board of Directors.
Latest Developments for Islet Sciences Inc
- Islet Sciences and BHV Pharma enter into merger agreement; combined company to be named Avogenx, Inc
- Islet Sciences Inc announces positive 12-Week phase 2 clinical results for SGLT2 Inhibitor Remogliflozin Etabonate
- Islet Sciences announces unregistered sale of equity securities - Form 8-K
- Islet Sciences, Inc to acquire BHV Pharma
Latest Key Developments in Biotechnology
- MediciNova, Inc announces FDA granted orphan drug designation to MN-001 for Idiopathic Pulmonary Fibrosis
- Acorda Therapeutics Inc completes acquisition of Civitas Therapeutics
- Transgenomic Inc announces $2.375 mln private placement financing
- Sangamo Biosciences Inc reiterates FY 2014 revenue guidance
- Share this
- Digg this